TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8550681

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin, 300 international units per kilogram of body weight per day
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin, 100 international units per kilogram of body weight per day
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 1650750

Group type: EXPERIMENTAL
Intervention: 4 U ACTH
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 micrograms CRH
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 12
Study: 6761096

Group type: EXPERIMENTAL
Intervention: Selective proximal vagotomy (SPV) plus ulcerectomy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Billroth I gastrectomy
Number of subjects: 41
Study: 31471967

Group type: EXPERIMENTAL
Intervention: Targeted Source Data Verification (SDV)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Full Source Data Verification (SDV)
Number of subjects: 126
Study: 29365196

Group type: EXPERIMENTAL
Intervention: Antenatal dexamethasone
Number of subjects: 310

Group type: COMPARATOR
Intervention: Control group (no antenatal dexamethasone)
Number of subjects: 310
Study: 26953770

Group type: EXPERIMENTAL
Intervention: Balloon Rectal Channel Catheter (BRCC)
Number of subjects: 54

Group type: COMPARATOR
Intervention: MRI without BRCC
Number of subjects: 54
Study: 24530403

Group type: EXPERIMENTAL
Intervention: AV7909 with low-dose (0.25mg/dose) CPG 7909
Number of subjects: 0

Group type: COMPARATOR
Intervention: AVA (Anthrax Vaccine Adsorbed, no CPG 7909)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AV7909
Number of subjects: 0

Group type: COMPARATOR
Intervention: AVA
Number of subjects: 0
Study: 22659714

Group type: EXPERIMENTAL
Intervention: Morphine (30 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 20412605

Group type: EXPERIMENTAL
Intervention: Multiple-micronutrient supplementation (20 mg Fe and 400 microg folic acid)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study: 18603822

Group type: EXPERIMENTAL
Intervention: Acarbose 300 mg/day for 12 months
Number of subjects: 84

Group type: COMPARATOR
Intervention: Non-acarbose group (control)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Acarbose group (subgroup analysis)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Non-acarbose group (subgroup analysis)
Number of subjects: 84
Study: 15823212

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 6 million units (6-MU) thrice weekly for 24 weeks
Number of subjects: 214

Group type: COMPARATOR
Intervention: Interferon-alpha 3 million units (3-MU) thrice weekly for 24 weeks
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Both 3-MU and 6-MU regimens
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: 6-MU regimen
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Non-cirrhotic patients
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 214
Study: 12377843

Group type: EXPERIMENTAL
Intervention: Inhaled flunisolide via metered‐dose inhaler (250 micro g per activation) eight puffs bid
Number of subjects: 40

Group type: COMPARATOR
Intervention: Systemic corticosteroids alone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 40
Study: 10357386

Group type: EXPERIMENTAL
Intervention: ddC/ZDV (zalcitabine 0.75 mg and zidovudine 200 mg every 8 h)
Number of subjects: 993

Group type: EXPERIMENTAL
Intervention: SQV/ZDV (saquinavir 600 mg and zidovudine 200 mg every 8 h)
Number of subjects: 993

Group type: EXPERIMENTAL
Intervention: SQV/ddC/ZDV (saquinavir 600 mg, zalcitabine 0.75 mg and zidovudine 200 mg every 8 h)
Number of subjects: 993

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 993
Study: 7584529

Group type: EXPERIMENTAL
Intervention: 50 micrograms ovine CRH administered intravenously as a bolus every hour from 0.00 hrs. to 6.00 hrs.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 1962062

Group type: EXPERIMENTAL
Intervention: Ubidecarenone (CoQ10) for 6 months
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ubidecarenone (CoQ10) for 3 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 44
Study: 31490257

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus dose followed by a 2 mg/kg/h continuous infusion during the intraoperative period, continued for 1 hour postsurgery)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 132
Study: 30670507

Group type: EXPERIMENTAL
Intervention: Self‐guided WorkPlan workbook with fortnightly telephone support calls
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 68
Study: 27012824

Group type: EXPERIMENTAL
Intervention: Grade III central PA mobilisation performed for 3 minutes at the level of the seventh thoracic vertebra (T7)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo group (less than grade I central PA mobilisation performed for 3 minutes at T7)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Both groups (experimental and placebo)
Number of subjects: 34
Study: 24610631

Group type: EXPERIMENTAL
Intervention: Low-dose iloprost (30 ng/kg/min)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: High-dose iloprost (50 ng/kg/min)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 23152362

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate and prednisone
Number of subjects: 1195

Group type: COMPARATOR
Intervention: Placebo and prednisone
Number of subjects: 1195
Study: 21448165

Group type: EXPERIMENTAL
Intervention: sorafenib plus IL‐2 (400 mg twice daily + 4.5 MIU five times per week for 6 in every 8 weeks)
Number of subjects: 128

Group type: COMPARATOR
Intervention: sorafenib alone
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: sorafenib plus IL‐2 (initial higher dose)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: sorafenib plus IL‐2
Number of subjects: 128
Study: 19958856

Group type: EXPERIMENTAL
Intervention: Elective intra-aortic balloon pump (IABP) insertion before high-risk PCI
Number of subjects: 300

Group type: COMPARATOR
Intervention: No planned IABP insertion
Number of subjects: 300
Study: 17479921

Group type: EXPERIMENTAL
Intervention: Accessing similar abstract representations of traits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Accessing irrelevant abstract representations of traits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reading a nonword prime
Number of subjects: 0

Group type: COMPARATOR
Intervention: Accessing knowledge of one's mother
Number of subjects: 0

Group type: COMPARATOR
Intervention: Accessing semantic knowledge
Number of subjects: 0
Study: 15208494

Group type: EXPERIMENTAL
Intervention: Radioiodine therapy (400 MBq)
Number of subjects: 201
Study: 11479653

Group type: EXPERIMENTAL
Intervention: Anti-cellulite product containing retinol, caffeine, and ruscogenine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 9494430

Group type: EXPERIMENTAL
Intervention: Water-cooled jacket with inlet water temperature maintained at 10-12 degrees C and flow rates of 2.6 +/- 0.3, 4.3 +/- 0.3, and 5.1 +/- 0.3 l/h.
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Water-cooled jacket
Number of subjects: 4
Study: 7527462

Group type: EXPERIMENTAL
Intervention: All‐Bond 2
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gluma 2000
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose
Number of subjects: 40

Group type: COMPARATOR
Intervention: Untreated (Control)
Number of subjects: 40
Study: 2847522

Group type: EXPERIMENTAL
Intervention: Enalaprilat (1.25 or 5.0 mg)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Furosemide (40 or 80 mg)
Number of subjects: 65
Study: 30866895

Group type: EXPERIMENTAL
Intervention: Personalised texting intervention (CRA summary letter + 24 weekly personalised text messages)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Non-personalised texting intervention (non-personalised letter + 24 weekly non-personalised text messages)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Personalised texting intervention
Number of subjects: 171

Group type: COMPARATOR
Intervention: Non-personalised texting intervention
Number of subjects: 171
Study: 28337893

Group type: EXPERIMENTAL
Intervention: Symbiotic treatment (Lactobacillus acidophilus NCFM, Bifidobacterium lactis, and fructo‐oligosaccharides) as adjunctive therapy
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard pharmacological treatment (nasal corticosteroid, oral antihistamine, and isotonic saline)
Number of subjects: 93
Study: 26183306

Group type: EXPERIMENTAL
Intervention: Nasogastric nutrition
Number of subjects: 146

Group type: COMPARATOR
Intervention: Family managed nutrition
Number of subjects: 146
Study: 23269991

Group type: EXPERIMENTAL
Intervention: TACE-RFA
Number of subjects: 189

Group type: COMPARATOR
Intervention: RFA
Number of subjects: 189
Study: 21029137

Group type: EXPERIMENTAL
Intervention: Point-by-point technique
Number of subjects: 66

Group type: COMPARATOR
Intervention: Catheter dragging technique
Number of subjects: 66
Study: 18300365

Group type: EXPERIMENTAL
Intervention: ARVs with hydroxyurea
Number of subjects: 59

Group type: COMPARATOR
Intervention: ARVs without hydroxyurea
Number of subjects: 59
Study: 17004898

Group type: EXPERIMENTAL
Intervention: Traditional Greek Mediterranean diet for 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard diet (subgroup B)
Number of subjects: 0
Study: 14580632

Group type: EXPERIMENTAL
Intervention: Simple reminder letter
Number of subjects: 1614

Group type: EXPERIMENTAL
Intervention: 2-month tailored stepped intervention
Number of subjects: 1614

Group type: EXPERIMENTAL
Intervention: 10-month tailored stepped intervention
Number of subjects: 1614

Group type: EXPERIMENTAL
Intervention: Self-choice of one of the above three strategies
Number of subjects: 1614
Study: 10779420

Group type: EXPERIMENTAL
Intervention: Subcutaneous bolus injection of deferoxamine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Subcutaneous continuous infusion of deferoxamine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Long-term efficacy of bolus injection
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Bolus injection
Number of subjects: 27
Study: 8776690

Group type: EXPERIMENTAL
Intervention: Pulmocare (high-fat formula)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ensure Plus (high-carbohydrate formula)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRC high carbohydrate formula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sugar-free Scandishake
Number of subjects: 0
Study: 1594552

Group type: EXPERIMENTAL
Intervention: Fungal lipase
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Creon (conventional pancreatin microsphere)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pancrex M (newer microsphere preparation)
Number of subjects: 10
Study: 3976336

Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Naloxone (0.01 mg/kg, i.m.)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 15
Study: 31347692

Group type: EXPERIMENTAL
Intervention: Fe‐Gly (60 mg Fe/kg)
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Fe‐Gly (60, 80 mg Fe/kg)
Number of subjects: 810

Group type: COMPARATOR
Intervention: Fe‐Gly (40 mg Fe/kg)
Number of subjects: 810

Group type: COMPARATOR
Intervention: Control (FeSO4, 60 mg Fe/kg)
Number of subjects: 810
Study: 30413216

Group type: EXPERIMENTAL
Intervention: Art Therapy (AT)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Music Reminiscence Activity (MRA)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (standard care without any intervention)
Number of subjects: 68
Study: 28531643

Group type: EXPERIMENTAL
Intervention: LNS (lipid-based nutrient supplements)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: LNS-VM (lipid-based nutrient supplements with vitamins and minerals)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: LNS-VM
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: LNS
Number of subjects: 130
Study: 24695878

Group type: EXPERIMENTAL
Intervention: Fluoroscopic cervical paramidline interlaminar epidural steroid injection (ESI)
Number of subjects: 143
Study: 22278649

Group type: EXPERIMENTAL
Intervention: High-intensity stretch home mechanical therapy (n = 11)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-intensity stretch home mechanical therapy (n = 9)
Number of subjects: 20
Study: 20194929

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance with a nonstimulating catheter
Number of subjects: 40

Group type: COMPARATOR
Intervention: Electrical stimulation (ES) with a stimulating catheter
Number of subjects: 40
Study: 17919698

Group type: EXPERIMENTAL
Intervention: Sheath group (n = 49) using Disposable Slide‐On sheaths and CST‐2000 Flexible Cystoscope System
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (n = 21) using standard 16F flexible cystoscope with Rapicide
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (n = 27) using standard 16F flexible cystoscope with Cidex OPA
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 15198451

Group type: EXPERIMENTAL
Intervention: Neurological examination (focused neurological examination)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Three step motor sequencing and horizontal visual tracking tests
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (subjects without PVWD)
Number of subjects: 48
Study: 12586131

Group type: EXPERIMENTAL
Intervention: Aspirin bolus (500 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ticlopidin (500 mg loading dose)
Number of subjects: 50

Group type: COMPARATOR
Intervention: PFA-100
Number of subjects: 50

Group type: COMPARATOR
Intervention: Aggregometry
Number of subjects: 50
Study: 9501951

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 18

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 18
Study: 7653794

Group type: COMPARATOR
Intervention: Standard PA catheter with intermittent SvO2 and CO measurements (6 times a day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Continuous SvO2 monitoring using a fiberoptic PA catheter
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Continuous CO monitoring using a newly developed PA catheter
Number of subjects: 30
Study: 2719237

Group type: EXPERIMENTAL
Intervention: Mandatory minute volume (MMV) weaning
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intermittent mandatory ventilation (IMV)
Number of subjects: 40
Study: 367795

Group type: EXPERIMENTAL
Intervention: Paracetamol (0.5 g X 4 for 3 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (0.5 g X 4 for 3 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All treatments (Paracetamol, Acetylsalicylic acid, Placebo)
Number of subjects: 30
Study: 31606939

Group type: EXPERIMENTAL
Intervention: Continuous NB‐UVB therapy (Side A)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Interrupted NB‐UVB therapy (Side B)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Continuous NB‐UVB treatment (Group 2)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Interrupted NB‐UVB treatment (Group 3)
Number of subjects: 23
Study: 30096700

Group type: EXPERIMENTAL
Intervention: Energy increased avocado added (AA)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Isoenergic avocado inclusive (AI)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Avocado-free control (C)
Number of subjects: 26
Study: 27189212

Group type: EXPERIMENTAL
Intervention: Bosentan dosing regimen
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Dried Blood Spot (DBS) analysis
Number of subjects: 64

Group type: COMPARATOR
Intervention: Plasma analysis
Number of subjects: 64
Study: 25212693

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 22170367

Group type: EXPERIMENTAL
Intervention: caffeine (3 mg caffeine/kg)
Number of subjects: 110

Group type: COMPARATOR
Intervention: decaf (control)
Number of subjects: 110
Study: 20619540

Group type: EXPERIMENTAL
Intervention: Attention Training Technique (ATT)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 103
Study: 17696221

Group type: EXPERIMENTAL
Intervention: Current and emerging therapies for HRS
Number of subjects: 0
Study: 15827365

Group type: EXPERIMENTAL
Intervention: Topical glyceryl trinitrate (1.25 mg/24-h)
Number of subjects: 53
Study: 12467854

Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound (US) assessment of bone status using DBM Sonic 1200
Number of subjects: 54

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Moderate- and high-risk patients
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Patients and controls
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Patients
Number of subjects: 54

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 54
Study: 10540564

Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (dry powder with ISF system) 12 mcg twice daily
Number of subjects: 160

Group type: COMPARATOR
Intervention: Salbutamol (200 mg qid)
Number of subjects: 160
Study: 8535647

Group type: COMPARATOR
Intervention: Sulphasalazine (SASP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination studies and meta-analyses
Number of subjects: 0
Study: 2147582

Group type: EXPERIMENTAL
Intervention: Antitumor B (Chinese herbs)
Number of subjects: 9633

Group type: EXPERIMENTAL
Intervention: Retinamide
Number of subjects: 9633

Group type: EXPERIMENTAL
Intervention: Riboflavin
Number of subjects: 9633

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9633
Study: 7032291

Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg every 6 hours)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg every 6 hours)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31060099

Group type: EXPERIMENTAL
Intervention: Static CAIS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dynamic CAIS
Number of subjects: 60
Study: 28741044

Group type: EXPERIMENTAL
Intervention: Asenapine (5-10 mg/day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Olanzapine (5-10 mg/day)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 51
Study: 26381400

Group type: EXPERIMENTAL
Intervention: 14-hour training program on MUPS communication skills
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (untrained doctors)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Training evaluation
Number of subjects: 123
Study: 24583541

Group type: EXPERIMENTAL
Intervention: WBV-50 Hz [high amplitude]
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: WBV-30 Hz [low amplitude]
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham (control)
Number of subjects: 17
Study: 22260818

Group type: EXPERIMENTAL
Intervention: Oral clodronate 1600 mg daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Anti‐rheumatic therapy alone
Number of subjects: 60
Study: 20122153

Group type: EXPERIMENTAL
Intervention: After-school academic support with additional learning materials
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: After-school academic support with additional learning materials and additional kit for girls (uniform and clothes)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Control group (107 villages from CHAMPION trial)
Number of subjects: 214
Study: 17925339

Group type: EXPERIMENTAL
Intervention: Weight reduction intervention (12-week weight reduction followed by 4-week weight stabilization)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (16-week weight maintenance)
Number of subjects: 0
Study: 16330884

Group type: EXPERIMENTAL
Intervention: Growth hormone substitution in GH‐deficient patients
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 26
Study: 12000778

Group type: EXPERIMENTAL
Intervention: DOTS with direct observation by health workers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DOTS with direct observation by family members
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DOTS without direct observation (self-administered)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community health worker sub-group
Number of subjects: 0
Study: 9798134

Group type: EXPERIMENTAL
Intervention: 7-day estrogen matrix patch (Climara) at 0.5 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7-day estrogen matrix patch (Climara) at 0.1 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.625-mg/day oral conjugated equine estrogen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7-day estrogen patch
Number of subjects: 0
Study: 7605184

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (n = 7) for 12 weeks at a mean intensity of 73% HRmax
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 47
Study: 2193835

Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (5-HTP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 6996120

Group type: EXPERIMENTAL
Intervention: sotalol 160 - 800 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: atenolol 100 - 500 mg
Number of subjects: 25
Study: 30088030

Group type: EXPERIMENTAL
Intervention: Mobile-bearing TKA (TiN-coated prostheses)
Number of subjects: 140
Study: 28148669

Group type: EXPERIMENTAL
Intervention: Cemented hemiarthroplasty
Number of subjects: 252

Group type: COMPARATOR
Intervention: Cemented total hip arthroplasty (THA)
Number of subjects: 252
Study: 25458336

Group type: EXPERIMENTAL
Intervention: Exercisers (≥150min of exercise/week)
Number of subjects: 1281

Group type: EXPERIMENTAL
Intervention: Exercisers
Number of subjects: 1281

Group type: COMPARATOR
Intervention: Non-exercisers
Number of subjects: 1281